Secretion of an immunoreactive single-chain variable fragment antibody against mouse interleukin 6 by Lactococcus lactis

Applied Microbiology and Biotechnology

Volumn 101, Issue 1, 2017, Pages 341-349

  Shigemori, Suguru ^a,b   Ihara, Masaki ^a   Sato, Takashi ^c   Yamamoto, Yoshinari ^a,b   Nigar, Shireen ^a,d   Ogita, Tasuku ^a   Shimosato, Takeshi ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d JASHORE UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Bangladesh)

Author keywords

gmLAB; Immunoreactivity; Interleukin 6; Lactococcus lactis; scFv antibody

Indexed keywords

CHAINS; DISEASE CONTROL; DISEASES; IMMUNOLOGY; LACTIC ACID; MAMMALS; PHYSIOLOGY;

GENETICALLY MODIFIED; GMLAB; IMMUNOREACTIVITIES; INTERLEUKIN-6; LACTIC ACID BACTERIA; LACTOCOCCUS LACTIS; RESEARCH AND DEVELOPMENT; SINGLE-CHAIN VARIABLE FRAGMENT ANTIBODIES;

ANTIBODIES;

CELL EXTRACT; IMIDAZOLE; NISIN; POLYHISTIDINE TAG; RECOMBINANT INTERLEUKIN 6; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; INTERLEUKIN 6; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANTIBODY; BACTERIUM; CANCER; DISEASE VECTOR; IMMUNE RESPONSE; MUCUS; PROTEIN; RODENT; SECRETION;

AMINO TERMINAL SEQUENCE; ANTIBODY PRODUCTION; ARTICLE; CELL GROWTH; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOREACTIVITY; LACTOCOCCUS LACTIS; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; TURBIDITY; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; ELECTROPORATION; GENETICS; METABOLISM; PLASMID; SECRETION (PROCESS);

LACTOCOCCUS LACTIS;

ANIMALS; CLONING, MOLECULAR; ELECTROPORATION; GENE EXPRESSION; INTERLEUKIN-6; LACTOCOCCUS LACTIS; MICE; PLASMIDS; PROTEIN BINDING; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84990874025     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-016-7907-8     Document Type: Article

References (47)

1. Ai C, Zhang Q, Ren C, Wang G, Liu X, Tian F, Zhao J, Zhang H, Chen YQ, Chen W (2014) Genetically engineered Lactococcus lactis protect against house dust mite allergy in a BALB/c mouse model. PLoS One 9(10):e109461. doi:10.1371/journal.pone.0109461
2. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF (2000) Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 6(5):583–588. doi:10.1038/75068
3. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, Pope SH, Riordan GS, Whitlow M (1988) Single-chain antigen-binding proteins. Science 242(4877):423–426
4. Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn’s disease. Clin Gastroenterol Hepatol 4(6):754–759. doi:10.1016/j.cgh.2006.03.028
5. Chu DK, Al-Garawi A, Llop-Guevara A, Pillai RA, Radford K, Shen P, Walker TD, Goncharova S, Calhoun WJ, Nair P, Jordana M (2015) Therapeutic potential of anti-IL-6 therapies for granulocytic airway inflammation in asthma. Allergy Asthma Clin Immunol 11(1):14. doi:10.1186/s13223-015-0081-1
6. De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A (2012) Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 367(25):2385–2395. doi:10.1056/NEJMoa1112802
7. de Ruyter PG, Kuipers OP, Beerthuyzen MM, van Alen-Boerrigter I, de Vos WM (1996) Functional analysis of promoters in the nisin gene cluster of Lactococcus lactis. J Bacteriol 178(12):3434–3439
8. Hanson ML, Hixon JA, Li W, Felber BK, Anver MR, Stewart CA, Janelsins BM, Datta SK, Shen W, McLean MH, Durum SK (2014) Oral delivery of IL-27 recombinant bacteria attenuates immune colitis in mice. Gastroenterology 146(1):210–221.e13. doi:10.1053/j.gastro.2013.09.060
9. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265(3):621–636
10. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23(9):1126–1136. doi:10.1038/nbt1142
11. Huibregtse IL, Snoeck V, de Creus A, Braat H, De Jong EC, Van Deventer SJ, Rottiers P (2007) Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin. Gastroenterology 133(2):517–528. doi:10.1053/j.gastro.2007.04.073
12. Hunter CA, Jones SA (2015) IL-6 as a keystone cytokine in health and disease. Nat Immunol 16(5):448–457. doi:10.1038/ni.3153
13. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552. doi:10.1002/art.27221
14. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology 126(4):989–996 discussion 947
15. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, Fischer M, Neurath MF, Rose-John S (2001) Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 268(1):160–167
16. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman’s disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20(6):304–311
17. Kishimoto T (2005) Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Microbiol 23:1–21
18. Kitaba S, Murota H, Terao M, Azukizawa H, Terabe F, Shima Y, Fujimoto M, Tanaka T, Naka T, Kishimoto T, Katayama I (2012) Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 180(1):165–176. doi:10.1016/j.ajpath.2011.09.013
19. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, van Dollenweerd C, Ma JK, Hammarstrom L (2002) In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 20(7):702–706. doi:10.1038/nbt0702-702
20. Kuipers OP, de Ruyter P, Kleerebezem M, de Vos WM (1998) Quorum sensing-controlled gene expression in lactic acid bacteria. J Biotechnol 64(1):15–21
21. Mierau I, Kleerebezem M (2005) 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl Microbiol Biotechnol 68(6):705–717. doi:10.1007/s00253-005-0107-6
22. Motta JP, Bermudez-Humaran LG, Deraison C, Martin L, Rolland C, Rousset P, Boue J, Dietrich G, Chapman K, Kharrat P, Vinel JP, Alric L, Mas E, Sallenave JM, Langella P, Vergnolle N (2012) Food-grade bacteria expressing elafin protect against inflammation and restore colon homeostasis. Sci Transl Med 4(158):158ra144. doi:10.1126/scitranslmed.3004212
23. Nelson AL (2010) Antibody fragments: hope and hype. MAbs 2(1):77–83
24. Nelson AL, Reichert JM (2009) Development trends for therapeutic antibody fragments. Nat Biotechnol 27(4):331–337. doi:10.1038/nbt0409-331
25. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627–2632. doi:10.1182/blood-2004-12-4602
26. + regulatory T cells. J Autoimmun 40:45–57. doi:10.1016/j.jaut.2012.07.012
27. Rincon M, Irvin CG (2012) Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 8(9):1281–1290. doi:10.7150/ijbs.4874
28. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G, Van Huynegem K, Steidler L, Caluwaerts S, Demetter P, Wasserfall CH, Atkinson MA, Dotta F, Rottiers P, Van Belle TL, Mathieu C (2014) Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 63(8):2876–2887. doi:10.2337/db13-1236
29. Sambrook J, Russell D (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory, Cold Spring Harbor
30. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9(7):671–675
31. Shigemori S, Yonekura S, Sato T, Otani H, Shimosato T (2013) Expression of the immunoreactive buckwheat major allergenic storage protein in Lactococcus lactis. Appl Microbiol Biotechnol 97(8):3603–3611. doi:10.1007/s00253-012-4608-9
32. Shigemori S, Oshiro K, Wang P, Yamamoto Y, Wang Y, Sato T, Uyeno Y, Shimosato T (2014) Generation of dipeptidyl peptidase-IV-inhibiting peptides from β-lactoglobulin secreted by Lactococcus lactis. Biomed Res Int 2014:393598. doi:10.1155/2014/393598
33. Shigemori S, Watanabe T, Kudoh K, Ihara M, Nigar S, Yamamoto Y, Suda Y, Sato T, Kitazawa H, Shimosato T (2015) Oral delivery of Lactococcus lactis that secretes bioactive heme oxygenase-1 alleviates development of acute colitis in mice. Microb Cell Factories 14(1):189. doi:10.1186/s12934-015-0378-2
34. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG (2013) Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 72(1):118–128. doi:10.1136/annrheumdis-2012-201310
35. Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B (2014) Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 73(9):1616–1625. doi:10.1136/annrheumdis-2013-205137
36. Song L, Smith MA, Doshi P, Sasser K, Fulp W, Altiok S, Haura EB (2014) Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J Thorac Oncol 9(7):974–982. doi:10.1097/jto.0000000000000193
37. Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW Jr, Gordon R, Hsu B (2013) Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum 65(10):2661–2671. doi:10.1002/art.38091
38. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, Caluwaerts S, Galleri L, Spagnuolo I, Steidler L, Van Huynegem K, Demetter P, Wasserfall C, Atkinson MA, Dotta F, Rottiers P, Gysemans C, Mathieu C (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122(5):1717–1725. doi:10.1172/jci60530
39. Tanaka T, Kishimoto T (2011) Immunotherapy of tocilizumab for rheumatoid arthritis. J Clin Cell Immunol S6:001. doi:10.4172/2155-9899.S6-001
40. Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6(10):16. doi:10.1101/cshperspect.a016295
41. Villarejo MR, Zabin I (1974) β-galactosidase from termination and deletion mutant strains. J Bacteriol 120(1):466–474
42. Voller A, Bartlett A, Bidwell DE (1978) Enzyme immunoassays with special reference to ELISA techniques. J Clin Pathol 31(6):507–520
43. Waldner MJ, Neurath MF (2014) Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 26(1):75–79. doi:10.1016/j.smim.2013.12.003
44. Wang Y, Yamamoto Y, Shigemori S, Watanabe T, Oshiro K, Wang X, Wang P, Sato T, Yonekura S, Tanaka S, Kitazawa H, Shimosato T (2015) Inhibitory/suppressive oligodeoxynucleotide nanocapsules as simple oral delivery devices for preventing atopic dermatitis in mice. Mol Ther 23(2):297–309. doi:10.1038/mt.2014.239
45. Yamamoto M, Yoshizaki K, Kishimoto T, Ito H (2000) IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 164(9):4878–4882
46. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T (2008) Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 371(9617):998–1006. doi:10.1016/s0140-6736(08)60454-7
47. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9(11):798–809. doi:10.1038/nrc2734